Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer.

Autor:	Moeller J; Oncology Specialty Pharmacy Services, Charles S. Kettles VA Medical Center, Ann Arbor, MI, USA., Green MD; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.; Department of Radiation Oncology, Charles S. Kettles VA Medical Center, Ann Arbor, MI, USA.; Lung Precision Oncology Program, Charles S. Kettles VA Medical Center, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA., Ramnath N; Lung Precision Oncology Program, Charles S. Kettles VA Medical Center, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.; Division of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.; Section of Medical Oncology, Charles S. Kettles VA Medical Center, Ann Arbor, MI, USA.
Jazyk:	angličtina
Zdroj:	Translational lung cancer research [Transl Lung Cancer Res] 2024 Jun 30; Vol. 13 (6), pp. 1444-1449. Date of Electronic Publication: 2024 Jun 18.
DOI:	10.21037/tlcr-24-111
Abstrakt:	Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-24-111/coif). M.D.G. participates in the Rogel Cancer Center DSMB at the University of Michigan as a volunteer. The other authors have no conflicts of interest to declare.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu